COMMUNIQUÉS West-GlobeNewswire

Novo Nordisk A/S - Share repurchase programme
06/06/2017
Bagsværd, Denmark, 06 June 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
Helsinn Group signs Exclusive Agreement with Purdue Pharma (Canada) for the Distribution and Licensing Rights of Aloxi® (palonosetron hydrochloride) in Canada
06/06/2017
Helsinn Group signs Exclusive Agreement with Purdue Pharma (Canada) for the Distribution and Licensing Rights of Aloxi ® (palonosetron hydrochloride) in Canada Lugano, Switzerland and Pickering, Canada, June 6, 2017 - [...]
Verona Pharma plc : Holding(s) in Company
06/06/2017
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Verona Pharma Plc 2 Reason for the notification (please [...]
uniQure Announces Appointment of Steven L. Zelenkofske as Chief Medical Officer
06/06/2017
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 06, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced the appointment of Steven L. Zelenkofske, D.O., as Chief [...]
Verona Pharma plc : Holding(s) in Company
06/06/2017
For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting [...]
Affimed Presents Data on First-in-Class BCMA-Targeting Immune Cell Engager AFM26 at ASCO Annual Meeting 2017
06/06/2017
Heidelberg, Germany, June 6, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that the Company [...]
Helsinn: First Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, supported by Helsinn, awarded to Dr Sarah A Buckley
06/06/2017
First Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Dr. Sarah A. Buckley, MD, University of Washington Lugano, Switzerland, [...]
Ortho Clinical Diagnostics VITROS(R) NephroCheck(R) Test for Prediction of Acute Kidney Injury Cleared, Available in Europe
06/06/2017
New test expands Ortho's VITROS(R) menu RARITAN, NJ--(Marketwired - Jun 6, 2017) - Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced the launch of its VITROS® NephroCheck® test, the [...]
Basilea announces presentation of interim phase 1/2a clinical data with anticancer drug candidate BAL101553 at ASCO meeting
06/06/2017
Basel, Switzerland, June 6, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that updates were presented on the ongoing clinical phase 1/2a program with its anticancer drug candidate BAL101553, a novel [...]
Novartis drug Tasigna receives EU approval for inclusion of Treatment-free Remission (TFR) data in product label
06/06/2017
Tasigna is the first and only tyrosine kinase inhibitor (TKI) to include information on stopping therapy in Ph+ CML-CP patients in the EU product information Approval based on Novartis trials evaluating TFR with Tasigna [...]
Targovax presents further positive clinical data from TG01 phase I/II trial at 2017 ASCO annual meeting
06/06/2017
Oslo, Norway, 6 June 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target treatment-resistant solid tumors, today announces that [...]
VALNEVA Présentera à la Conférence Global Healthcare 2017 de Jefferies à New York
06/06/2017
Valneva Présentera à la Conférence Global Healthcare 2017 de Jefferies à New York Lyon (France), 6 juin 2017 - Valneva SE ("Valneva" ou "le Groupe"), société de biotechnologie dédiée au développement, à la production et [...]
VALNEVA to Present at Jefferies 2017 Global Healthcare Conference in New York
06/06/2017
Valneva to Present at Jefferies 2017 Global Healthcare Conference in New York Lyon (France), June 06, 2017 - Valneva SE ("Valneva" or "the Company"), a fully integrated, commercial stage biotech company focused on [...]
Targovax announces formal agenda for 2017 Capital Markets Updates in Oslo and London
06/06/2017
Oslo, Norway, 6 June 2017 - Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces formal agenda for its Capital [...]
Addex Annual General Meeting Scheduled for 22 June 2017
06/06/2017
Geneva, Switzerland 6 June 2017 - Addex Therapeutics (SIX: ADXN), announced today that its Annual General Meeting will take place on Thursday, 22 June 2017, at 11:00am at the Campus Biotech, Chemin des Mines 9, 1202 [...]
Michael Phelps, athlète champion du monde et défenseur de la santé mentale, nommé au Conseil d'administration de Medibio
06/06/2017
SYDNEY, Australie, le 6 juin 2017 (GLOBE NEWSWIRE) - Medibio Limited (ASX : MEB) (MEB ou la Société), société de technologie médicale cotée sur ASX qui a développé un test objectif efficace pour aider au diagnostic de [...]
Novartis announces clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancer
05/06/2017
Phase I/II study to evaluate Mekinist ® (trametinib) in combination with Opdivo ® (nivolumab) and Opdivo + Yervoy ® (ipilimumab) Collaboration expands upon existing clinical investigation of Opdivo combination with [...]
NANOBIOTIX : données prometteuses de l'essai de phase I/II dans les cancers de la Tête et du Cou avec NBTXR3 ; présentées au Congres Annuel de L'ASCO
05/06/2017
NANOBIOTIX : DONNEES PROMETTEUSES DE l'ESSAI DE PHASE I/II DANS LES CANCERS DE LA TETE ET DU COU AVEC NBTXR3 ; PRESENTEES AU CONGRES ANNUEL DE L'ASCO Très bon profil de sécurité sans aucun effet indésirable chez des [...]
NANOBIOTIX : promising data from phase I/II Head and Neck cancer trial with NBTXR3 presented at the American Society of Clinical Oncology's Annual Meeting
05/06/2017
NANOBIOTIX: PROMISING DATA FROM PHASE I/II HEAD AND NECK CANCER TRIAL WITH NBTXR3 PRESENTED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY'S ANNUAL MEETING Very good safety profile with no AEs and SAEs in stage III/IV in [...]

Pages